Stockscreener 앱 받기
1.78
3.26%
-0.06
시간 외 거래:
1.81
0.03
+1.69%
전일 마감가:
$1.84
열려 있는:
$1.85
하루 거래량:
382.89K
Relative Volume:
0.55
시가총액:
$77.69M
수익:
$55,200
순이익/손실:
$-21.24M
주가수익비율:
-3.0246
EPS:
-0.5885
순현금흐름:
$-19.37M
1주 성능:
+1.14%
1개월 성능:
-6.56%
6개월 성능:
-9.18%
1년 성능:
+2.89%
1일 변동 폭
$1.775
$1.8827
1주일 범위
$1.775
$1.9733
52주 변동 폭
$1.53
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.78 | 77.69M | 55,200 | -21.24M | -19.37M | -0.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference - investingnews.com
Gain Therapeutics Announces CEO Gene Mack to Participate in ROTH Healthcare Opportunities Conference Panel and One-on-One Meetings - Quiver Quantitative
HLS Therapeutics Inc. (TSX:HLS) Gains Momentum as Cardiovascular Growth and Balance Sheet Improvement Support Investor Confidence - kalkine.ca
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com
H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
GANX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates Despite Share SlipAnalyst Drop Coverage - dars.gov.et
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Gain (GANX) Price: Moves 0.25% Lower to $2.00 in the Latest Reading; Levels: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotFactor Timing - dars.gov.et
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn
Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn
GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
BTIG Research Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - MarketBeat
Gain Therapeutics, Inc. Q2 2026: Net loss $4.7M, EPS $(0.11) — 10-Q Summary - TradingView
Gain Therapeutics (GANX) faces going-concern risk while advancing Parkinson’s drug - Stock Titan
Gain Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Gain Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows - scanx.trade
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall - TradingView
Gain Therapeutics 2Q Loss/Shr 11c >GANX - Moomoo
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update - Yahoo Finance
Gain Therapeutics (GANX) Advances 2% as Support at $1.72 HoldsVWAP Deviation - careplusvn.com
Gain Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Gain Therapeutics Inc (GANX) Stock News Today - TradingKey
Gain Therapeutics (GANX) Edges Higher as Shares Hold Key $1.74 SupportHagopian Line - dars.gov.et
Gain Therapeutics (GANX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
GANX Q1 2026 Earnings: Narrowed Loss Beats Expectations as Stock RetreatsEPS Miss Report - careplusvn.com
Gain Therapeutics (GANX) Quietly Holds at $1.68 – Support Tightens Near Recent LowsVirgin POC - dars.gov.et
Gain Therapeutics, Inc. Revenue Breakdown – NASDAQ:GANX - tradingview.com
GANX|Gain Therapeutics Inc|Price:1.855|Chg%:+0.105 - TradingKey
Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gain Therapeutics Inc (GANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GANX|Gain Therapeutics Inc|Price:1.850|Chg%:-0.010 - TradingKey
Gain Therapeutics Inc (GANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gain Therapeutics Inc (GANX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Gain Therapeutics Inc (GANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GANX|Gain Therapeutics Inc|Price:1.840|Chg%:-0.110 - TradingKey
Gene-editing company Scribe Therapeutics' IPO soars in debut after raising more money than expected - The Business Journals
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):